TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30703494
Drug: Fufang Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Danshen Dripping Pill (FDDP)
Study: 30703494
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clopidogrel and FDDP
Study: 29663464
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg (30 mg for dose reduction)
Study: 22005174
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment (SCT)
Study: 20599140
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) before therapy sessions
Study: 15901634
Drug: leflunomide 20
Normalized name: leflunomide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: leflunomide 20 mg daily (n=30)
Study: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NCR) 1/8-2 mg
Study: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NCR) 1/32 mg or more
Study: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NCR) 1/4 mg or less
Study: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NCR) 1/8-1/4 mg
Study: 7722961
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with insulin
Study: 25238659
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (leuprolide acetate 1 mg s.c. injection 3 days after ET)
Study: 25238659
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (two sequential doses of leuprolide acetate 1 mg s.c. injections 3 and 6 days after ET)
Study: 21813073
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment (2 to 6 mg/d) for 2 weeks
Study: 21813073
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment (10 to 20 mg/d) for 10 weeks (for nonresponders)
Study: 21122046
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment for 49 weeks
Study: 21122046
Drug: Hot wax
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot wax treatment for 49 weeks
Study: 19034126
Drug: unpreserved 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: unpreserved 0.4% hyaluronic acid eye drops 150 mOsm/L
Study: 19034126
Drug: unpreserved 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: unpreserved 0.4% hyaluronic acid eye drops 300 mOsm/L
Study: 16025230
Drug: Acute ACE-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute ACE-inhibitor treatment (< 9 hours after MI)
Study: 14728070
Drug: trimetazidine MR
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimetazidine MR 35 mg
Study: 11015815
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg/d
Study: 19440083
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/d
Study: 22776634
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 mg/d
Study: 2647933
Drug: Increased oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased oral cyclosporine dose for 7 to 10 days
Study: 11287776
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy
Study: 29157293
Drug: Memantine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5 mg/day for 48 hours before surgery, increased to 10 mg/day for the first 24 hours after surgery, continued for 3 months)
Study: 23955138
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy (CTCX group)
Study: 23955138
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (CT group)
Study: 19137265
Drug: Acarbose (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (300 mg/day) for 3 months
Study: 17127704
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of peginterferon alpha‐2a and lamivudine
Study: 15185991
Drug: Functional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional training of dysphagia with oral care (once a week for 3 years)
Study: 15185991
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care (non-training group)
Study: 15185991
Drug: Functional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional training of dysphagia with oral care
Study: 3228824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both drugs
Study: 31112386
Drug: Budesonide-Formoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-Formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation as needed)
Study: 31112386
Drug: Albuterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (100 μg, two inhalations as needed)
Study: 31112386
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 μg, one inhalation twice daily) plus as-needed albuterol
Study: 28859664
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of aerobic exercise and cognitive training
Study: 8978226
Drug: Rehabilitation programmes
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation programmes comprising psychological therapy, counselling, relaxation training, and stress management training over seven weekly group outpatient sessions for patients and spouses.
Study: 6422914
Drug: High-titer alpha-interferon
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-titer alpha-interferon (100 X 10(6) IU/mL)
Study: 24731015
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training and review of airway clearance therapy (ACT) for 8 weeks
Study: 12091679
Drug: 125 mL
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL of contrast material at 2.5 mL/sec
Study: 12091679
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of contrast material at 2.0 mL/sec
Study: 12091679
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL of contrast material at 1.5 mL/sec
Study: 12091679
Drug: 70 mL
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mL of contrast material at 1.0 mL/sec
Study: 10069785
Drug: Exercise Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Training (ET) at 60% of peak VO2, initially 3 times a week for 8 weeks, then twice a week for 1 year
Study: 387497
Drug: Hydrocortisone alcoholic
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone alcoholic solution
Study: 31028547
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3D and NBI
Study: 31443072
Drug: Unfavorable outcome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfavorable outcome after aSAH treatment
Study: 28338977
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg d-cycloserine (DCS)
Study: 26278911
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rEPO), high-dose, repetitive administration
Study: 24123224
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg CR
Study: 24123224
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg CR
Study: 24123224
Drug: Isradipine 20
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine 20 mg CR
Study: 24123224
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg daily
Study: 8732377
Drug: Streptokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase with subcutaneous heparin
Study: 8732377
Drug: Streptokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase with intravenous heparin
Study: 1564212
Drug: Accelerated recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated recombinant tissue-type plasminogen activator (rt-PA) with intravenous heparin
Study: 1564212
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of streptokinase, rt-PA and intravenous heparin
Study: 2898025
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection treatment
Study: 31204383
Drug: Multiple small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple small incisions and negative-pressure wound therapy (NPWT)
Study: 31204383
Drug: Traditional comprehensive
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional comprehensive treatment with additional small incisions and NPWT
Study: 31204383
Drug: Traditional comprehensive
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional comprehensive treatment
Study: 30522663
Drug: Low-dose drug-coated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose drug-coated balloon (DCB)
Study: 24658598
Drug: Oral double-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral double-dose esomeprazole 40 mg twice daily (n=93)
Study: 24658598
Drug: Oral standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standard-dose esomeprazole 40 mg once daily (n=94)
Study: 19766977
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment with usual obstetric care
Study: 19766977
Drug: Usual obstetric
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual obstetric care and sham ultrasound treatment
Study: 16260511
Drug: Ultralow-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow-dose transdermal estradiol (0.014 mg/d)
Study: 11876692
Drug: rhIL‐11 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐11 15 microg/kg once weekly
Study: 11876692
Drug: rhIL‐11 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐11 7.5 microg/kg twice weekly
Study: 1670631
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g oral sulfasalazine plus 20 mg twice daily rectal prednisolone enemas (group I, N = 18)
Study: 1670631
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g twice daily rectal sucralfate enemas plus oral placebo (group II, N = 19)
Study: 6623019
Drug: Nonsteroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid anti-inflammatory drugs (NSAIDs)
Study: 6623019
Drug: Remission-inducing drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission-inducing drugs (RIDs)
Study: 28235887
Drug: Capsaicin administration
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin administration to evoke coughs
Study: 28235887
Drug: Methacholine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine administration to induce bronchoconstriction
Study: 26965791
Drug: Prednisolone 35
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 35 mg qd
Study: 12817520
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg qd
Study: 9106374
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment response
Study: 15701470
Drug: Optimal pacing
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pacing therapy
Study: 1535578
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.i.d.
Study: 7499006
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg q.d.
Study: 7499006
Drug: 14-hydroxy metabolite
Normalized name: 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-hydroxy metabolite with 500 mg q.d.
Study: 7499006
Drug: 14-hydroxy metabolite
Normalized name: 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-hydroxy metabolite with 250 mg b.i.d.
Study: 31993753
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (OC) - cooling the mouth with ice for ≥ 30 minutes during chemotherapy infusions.
Study: 31993753
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral cryotherapy).
Study: 31993753
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (OC).
Study: 27208923
Drug: SFO +
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFO + LEU (4.2 g of leucine)
Study: 27208923
Drug: SFO +
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFO + ALA (4.2 g of alanine)
Study: 25280603
Drug: Kyrobak (Radiancy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kyrobak (Radiancy, Hod-hasharon, Israel) self-treatment for 10 minutes, one to three times per day, for 3 weeks
Study: 25280603
Drug: Kyrobak (Radiancy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kyrobak (Radiancy, Hod-hasharon, Israel) self-treatment
Study: 23528101
Drug: rFVIII-FS prophylaxis
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIII-FS prophylaxis (25 IU kg(‐1), three times weekly)
Study: 21900595
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake levels of 3.4 g/d or less
Study: 21900595
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake levels of more than 3.4 g/d
Study: 21900595
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake levels of 30 g/d or less
Study: 21900595
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake levels of more than 30 g/d
Study: 19143021
Drug: Fractional radiofrequency
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional radiofrequency (FRF) treatment using Renesis device, delivering RF energy at 72 degrees C for 4 seconds.
Study: 15231555
Drug: Computerised cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive-behavioural therapy (CBT)
Study: 370042
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of supplementary vitamin C daily
Study: 30382496
Drug: Sequential practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential practice schedule
Study: 23494898
Drug: Guided Disclosure
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Disclosure Protocol (GDP) - writing about the patient's diagnosis and treatment for 15 minutes a day over 3 days
Study: 22180357
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/d, n = 47)
Study: 22180357
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/d, n = 45)
Study: 19691482
Drug: Tirofiban (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (50 ng mL(‐1))
Study: 19691482
Drug: PSI-697 (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSI-697 (low-dose 2 m)
Study: 19691482
Drug: PSI-697 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSI-697 (high-dose 20 m)
Study: 11468942
Drug: Mizolastine pediatric
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine pediatric solution (0.15 mg/kg once daily)
Study: 11468942
Drug: Mizolastine pediatric
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine pediatric solution
Study: 30247714
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (21 g protein, 3 g total leucine, 9 g carbohydrate, 3 g fat; n = 21)
Study: 30247714
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g protein, 25 g carbohydrate, 6 g fat; n = 20)
Study: 28643799
Drug: Aflibercept treatment
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept treatment initiated for nAMD
Study: 26632710
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy based on E‐test results (rabeprazole + bismuth potassium citrate + amoxicillin + clarithromycin) for 14 days
Study: 26632710
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy (rabeprazole + bismuth potassium citrate + amoxicillin + clarithromycin)
Study: 25098068
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose antibiotic before inguinal hernia mesh repair
Study: 14687438
Drug: rosuvastatin 10-40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10-40 mg
Study: 14687438
Drug: atorvastatin 10-80
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 10-80 mg
Study: 14687438
Drug: simvastatin 10-80
Normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: simvastatin 10-80 mg
Study: 14687438
Drug: pravastatin 10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 10-40 mg
Study: 9042739
Drug: Verbal-visual combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal-visual combination
Study: 20124953
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil with MPA-AUC less than 30 mg hr/L
Study: 20124953
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil with MPA-AUC more than or equal to 30 mg hr/L
Study: 20124953
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil with MPA-AUC less than 30 mg hr/L in tacrolimus-treated patients
Study: 20124953
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil with MPA-AUC more than or equal to 30 mg hr/L in tacrolimus-treated patients
Study: 16796276
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg alendronate once weekly
Study: 1360032
Drug: Routine doppler
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine doppler ultrasound examinations of the umbilical and uterine arteries during pregnancy (first at 19-22 weeks, then monthly for high risk or once at 32 weeks for low risk)
Study: 28235424
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Bobath therapy)
Study: 30641621
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (CM) - Astragalus Granule (AG)
Study: 30641621
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WM) - Basic treatment with aerosol inhalation (Budesonide suspension and Terbutaline Sulphate Solution)
Study: 23723319
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV vaccine (HPV16/18), administered at 0, 1, and 6 months
Study: 23723319
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV vaccine (HPV16/18)
Study: 22019331
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 μg, 2 doses per week for 48 weeks)
Study: 19436116
Drug: pilsicainide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: pilsicainide (150 mg/day)
Study: 19436116
Drug: bepridil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bepridil (200 mg/day)